drugset / Trial / NCT05611424
Gene Therapy for Wet AMD
Phase 1
Not yet recruiting
18 enrolled
Frontera Therapeutics
Peking Union Medical College Hospital · collabThe First Affiliated Hospital of Soochow University · collabThe First Affiliated Hospital of Zhengzhou University · collabTianjin Medical University Eye Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals. The available therapies for treating nAMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. Administration of FT-003 has the potential to treat nAMD by providing durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2024-11-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT-003 | Unknown | — | Other |